International policies guiding the selection, analysis, and clinical management of secondary findings from genomic sequencing: A systematic review.

Am J Hum Genet

Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada; Genomics Health Services Research Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada; Genetics Adviser, Toronto, ON, Canada. Electronic address:

Published: October 2024

AI Article Synopsis

  • Secondary findings (SFs) from genomic sequencing can greatly affect patient health, but guidelines for their clinical investigation are inconsistent, prompting a review of existing policies.
  • The review encompassed 63 SF policies from various international sources, focusing on SFs selection, analysis, and clinical management, and revealed that most guidelines address clinical management while fewer tackle selection and analysis.
  • Although policies scored well for scope and clarity, they fell short in rigor and applicability, indicating a need for improved practices in SFs analysis, clinical validation, and follow-up support to ensure evidence-based care.

Article Abstract

Secondary findings (SFs) from genomic sequencing can have significant impacts on patient health, yet existing practices guiding their clinical investigation are inconsistent. We systematically reviewed existing SFs policies to identify variations and gaps in guidance. We cataloged and appraised international policies from academic databases (n = 5, inception-02/2022) and international human genetic societies (n = 64; inception-05/2022), across the continuum of SFs selection, analysis, and clinical management. We assessed quality using AGREE-II and interpreted results using qualitative description. Of the 63 SFs policies identified, most pertained to clinical management of SFs (98%; n = 62; primarily consent and disclosure), some guided SFs analysis (60%; n = 38), while fewer mentioned SFs selection (48%; n = 30). Overall, policies recommend (1) identifying clinically actionable, pathogenic variants with high positive predictive values for disease (selection), (2) bioinformatically filtering variants using evidence-informed gene lists (analysis), and (3) discussing with affected individuals the SFs identified, their penetrance, expressivity, medical implications, and management (clinical management). Best practices for SFs variant analysis, clinical validation, and follow-up (i.e., surveillance, treatment, etc.) were minimally described. Upon quality assessment, policies were highly rated for scope and clarity (median score, 69) but were limited by their rigor and applicability (median scores, 27 and 25). Our review represents a comprehensive international synthesis of policy guiding SFs across the continuum of selection, analysis, and clinical management. Our synthesis will help providers navigate critical decision points in SFs investigation, although significant work is needed to address gaps in SFs analysis, clinical validation, and follow-up processes and to support evidence-based practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480791PMC
http://dx.doi.org/10.1016/j.ajhg.2024.08.012DOI Listing

Publication Analysis

Top Keywords

analysis clinical
20
clinical management
20
selection analysis
12
sfs
12
international policies
8
clinical
8
secondary findings
8
genomic sequencing
8
sfs policies
8
sfs selection
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!